Steroid GABA Modulators for Potent Neuropsychiatric Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuropsychiatric diseases such as anxiety, depression, and schizophrenia lack effective steroid compounds that can directly activate GABA(A) receptor subtypes outside the synapses, particularly α4β3δ, and face challenges with side effects like anesthesia and sedation.
Innovation Solution
Development of steroid compounds with specific structural features, including Formula (I) and Formula (II), which can act as GABA modulators to positively or negatively affect GABA(A) receptors, providing improved pharmacokinetic properties, oral bioavailability, stability, and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If steroid compounds are used to treat neuropsychiatric diseases, then therapeutic effects are achieved, but side effects such as anesthesia and sedation occur
Solution Approach 1:
The patent introduces specific substituents at defined positions on the steroid core structure to create localized functional modifications that enhance therapeutic activity while reducing unwanted side effects. Different R groups at different ring positions provide selective modulation of GABA(A) receptor subtypes.
Solution Approach 2:
The patent systematically varies chemical parameters including substituent types (R1-R6), ring saturation, and stereochemistry to optimize the balance between therapeutic efficacy and side effect profile. This includes modifying hydrophobicity, molecular size, and electronic properties of the steroid core.
2Power
If GABA(A) receptor activation is enhanced to treat neuropsychiatric diseases, then therapeutic potency is improved, but anesthesia and sedation side effects increase
Solution Approach 1:
The patent targets specific allosteric sites on GABA(A) receptor subtypes through localized structural features of the steroid compound, enabling selective activation of therapeutic pathways while avoiding overactivation that leads to sedation and anesthesia.
Solution Approach 2:
The steroid compounds are designed to interact with multiple GABA(A) receptor subtypes simultaneously, providing broad therapeutic coverage for various neuropsychiatric conditions while maintaining a favorable side effect profile through balanced multi-target engagement.
3Object-affected harmful factors
If steroid compound structure is modified to improve selectivity, then side effects are reduced, but synthesis complexity increases
Solution Approach 1:
The patent divides the steroid molecule into functional segments (rings A-D with specific R groups) that can be independently optimized and synthesized, then assembled through standardized coupling reactions, reducing overall synthesis complexity while maintaining selectivity.
Solution Approach 2:
The patent employs key intermediate structures and protecting group strategies that facilitate selective modifications at specific positions, enabling complex structural variations to be introduced through modular synthesis steps rather than complete de novo synthesis.
Data Source
AI summary
The present invention relates to a steroid compound, a use thereof and a preparation method therefor. It is expected that such compound can effectively treat mental and neurological diseases, and has good active efficacy, pharmacokinetic (PK) performance, oral bioavailability, stability, safety, clearance rate, and/or metabolic performance and the like.